Research and Markets: Anti-Infective Drugs Markets: Six Infectious Diseases Account for 50% of Premature Deaths Worldwide

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/e5d7cc/antiinfective_dru) has announced the addition of the "Anti-Infective Drugs Markets" report to their offering.

Six infectious diseases - pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS - account for half of all premature deaths worldwide, killing mostly children and young adults, according to the World Health Organization (WHO). Moreover, threatening pandemics such as swine flu (H1N1 influenza A virus) are adding significant pressure to already strained healthcare budgets of governments around the world.

This report analyzes the anti-infective drugs market and highlights the existing and developing anti-infectives used to ameliorate infectious diseases' afflictions on humankind. Anti-infective drugs include: anti-viral therapeutics, antibiotics, anti-fungal agents and prophylactic treatments such as vaccines. Particular attention is paid to the clinical market segment and the pharmaceutical/biotechnology companies involved in anti-infective drugs with specific emphasis on each company's sales focus, product portfolio and R&D pipeline.

To date, the most successful anti-infective drugs target the human immunodeficiency virus (HIV, the virus that causes AIDS), the herpes virus (HSV-1 and HSV-2), bacterial infections and hepatitis C (HCV). A number of exciting novel anti-viral and antibiotic compounds are currently revolutionizing anti-infective drugs markets, including Truvada and Valtrex, which are anti-HIV and anti-herpes therapies, respectively. Significant resources are also being dedicated toward hepatitis A (HAV), hepatitis B (HBV) and Staph infections, including MRSA.

What's more, this study will examine the existing and developing anti-infective drugs targeted at infectious diseases that continue to devastate developing countries, including: cholera, dengue fever, meningitis, rotavirus, typhoid and yellow fever.

Key Topics Covered:

  • Overview
  • Clinical Syndromes and Therapy
  • Anti-Infective Drugs Market
  • Description of Anti-Infective Therapeutic Agents
  • Market for Anti-Infective Drugs and Vaccines
  • Decision-making Activity in the Anti-Infective Drugs Market
  • Economics of Anti-Microbial Drug Resistance: The Persistent Need for Anti-Bacterials
  • Global Market Analysis of Anti-Infective Drugs
  • Global Market for Anti-Bacterial Therapies
  • Global Market for Anti-Fungal Therapies
  • Global Market for Anti-Viral Therapies
  • Market, Demographic and Economic Trends
  • Political/Legal Trends
  • Technological Trends
  • Socio-Cultural Trends
  • Competitive Landscape
  • Sales Performance amongst the Leading Players: Detailed Analysis of Leading Anti-Infective Players
  • Company Profiles

Companies Mentioned:

  • Adlyfe, Inc.
  • Advanced Life Sciences Holdings, Inc.
  • Affinium Pharmaceuticals
  • APP Pharmaceuticals
  • Aquapharm Biodiscovery
  • Basilea Pharmaceutica AG
  • Biophage Pharma, Inc.
  • CEL-SCI Corporation
  • Cerexa, Inc. (Subsidiary of Forest Laboratories)
  • Daiichi Sankyo Co., Ltd.
  • Hospira, Inc.
  • Incyte Corporation
  • Idenix Pharmaceuticals, Inc.
  • Medivir AB
  • Mutabilis
  • NanoBio Corporation
  • Nanosphere, Inc.
  • Novabay Pharmaceuticals, Inc.
  • Obetech, LLC
  • Optimer Pharmaceuticals, Inc.
  • Panacos Pharmaceuticals, Inc.
  • Paratek Pharmaceuticals, Inc.
  • Pharmasset, Inc.
  • Ribomed Biotechnologies, Inc.
  • Rib-X Pharmaceuticals, Inc.
  • Targanta Therapeutics Corporation, Inc. (Acquired by The Medicine Company)
  • Trius Therapeutics
  • Vertex Pharmaceuticals, Inc.
  • X-GEN Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/e5d7cc/antiinfective_dru



CONTACT:

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
[email protected]

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Infectious Diseases  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.